Skin Cancer

The AJMC® Skin Cancer compendium is a comprehensive resource for clinical news and expert insights about melanoma and other skin cancers.

Latest News

Patients who stopped adjuvant immunotherapy less than 12 months following metastatic melanoma resection did not experience inferior outcomes. | anna.stasiia - stock.adobe.com
Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

April 17th 2025

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Patient self reporting or intentional physical examinations by clinicians remain the main avenues by which suspected skin cancers are identified. | Image credit: anna.stasiia - stock.adobe.com
Novel Methods Could Reshape Skin Cancer Diagnostics

April 10th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com
Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

April 2nd 2025

Estrogen | Image credit: Debalina - stock.adobe.com
Estrogen Therapy May Increase Risk of 3 Skin Cancers

March 20th 2025

Doctor screening patient for skin cancer | Image credit: Seventyfour – stock.adobe.com
Patients Prefer AI in Skin Cancer Screening as an Assistive Tool, Not a Replacement

March 14th 2025

Dr. Jason Luke leads a panel discussing immunotherapy advances in Cutaneous and Basal Cell Carcinoma

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Melanoma graphic
August 3rd 2021

BRAF/MEK Inhibitors Effective in Patient With Rare Melanoma Mutation

Jared Kaltwasser
A report reviews the case of a patient with stage IV melanoma who, while having several issues with treatment toxicity, was later free of disease following treatment with BRAF and MEK inhibitors.
MDM2 Antagonists Help CDK4/6 Inhibitors Overcome Resistance in Melanoma
August 21st 2019

MDM2 Antagonists Help CDK4/6 Inhibitors Overcome Resistance in Melanoma

Laura Joszt, MA
Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) antagonist can help CDK4/6 inhibitors overcome resistance, offering a potential second-line treatment option in melanoma.
Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma
July 18th 2019

Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma

Jaime Rosenberg
A phase 2b clinical trial is producing promising results for a personalized cancer vaccine used in patients with stage III and IV resected melanoma.
Site Logo
May 1st 2019

Gathering and Using Real-World Data to Improve Patient Outcomes

Laura Joszt, MA
In a session at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, speakers highlighted a pilot program to gather and use real-world evidence to compare outcomes at 7 large academic medical centers for patients with rheumatoid arthritis, multiple sclerosis, and malignant melanoma.
Site Logo
February 14th 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

Mary Caffrey
Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.
Site Logo
February 12th 2019

Rutgers' Janice Mehnert, MD, on Biomarkers, Being Inclusive in Clinical Trials, and Taking Time to Weigh the Options

Mary Caffrey
From her vantage point at Rutgers Cancer Institute of New Jersey, Janice Mehnert, MD, has had a front-row seat to the immuno-oncology revolution. Mehnert returned to her alma mater in 2007, and since 2014, she has headed Rutgers’ Phase I/ Developmental Therapeutics Program; she is also head of the melanoma research team. Her work on the KEYNOTE-028 trial has produced important results in multiple cancers, including neuroendocrine tumors, thyroid cancer, small cell lung cancer, and, recently, advanced ovarian cancer.
Immunotherapy Improves Survival in Metastatic Melanoma
November 7th 2018

Immunotherapy Improves Survival in Metastatic Melanoma

David Bai, PharmD
The use of CTLA-4, PD-1, or a combination approach achieved high response rates and improved overall survival in patients with CDKN2A mutations with metastatic melanoma, based on the results of a study by Helgadottir et al.
New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing
November 1st 2018

New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing

Laura Joszt, MA
New guidelines released by the American Academy of Dermatology will help physicians provide the best treatment for more than 1 million Americans living with melanoma, the deadliest form of skin cancer. The guidelines also highlight the importance of discussions between physicians and patients.
<12345

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo